Market cap (billions): $83.6
P/E ratio*: 19
Earnings growth**: 11%
Dividend yield: 2.6%
Abbott Laboratories, the fourth-largest drugmaker in terms of annual sales, has had tremendous success with fast-growing drugs like Humira, an anti-inflammatory, and Kaletra, an HIV
treatment. Earnings in its last quarter surged 35%.
Despite the success of its pharmaceutical division, CEO Miles White is determined to keep focusing on the company's medical devices branch, which has emerged as a leader in
drug-coated stents. White thinks this approach will help Abbott weather the regulatory and patent-related stumbling blocks that are hitting its pure pharma rivals.
NEXT: GROWTH AND INCOME: Coca-Cola